Jianfeng Group 2017-017 (Announcement on Illegal Trading of Stocks by Senior Managers of the Company and Apology)
Release time:
2020-08-05
Securities Code: 600668 Securities Abbreviation: Jianfeng Group Announcement No.: 2017-017
Bond Abbreviation: 13 Peak 01 Bond Code: 122227
Bond Abbreviation: 13 Peak 02 Bond Code: 122344
Zhejiang Jianfeng Group Co., Ltd.
Announcement
on Illegal Stock Trading and Apology by Senior Managers of the Company The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
On July 19, 2017 , Zhejiang Jianfeng Group Co., Ltd. (hereinafter referred to as "the company" and "the company") received a report from Mr. Zhang Fengliang, deputy general manager of the company. There is a situation of illegal trading of company stocks in its securities account. The relevant matters are hereby disclosed as follows:
Basic information of 1.'s stock trading
Mr. Zhang Fengliang was appointed as the senior manager (deputy general manager) of the company on November 12, 2014 . Mr. Zhang Fengliang has been working in other places for a long time, and his stock account is managed by his family members. His family members bought 2,200 shares of the company's stock on July 17, , 2017 , without the knowledge of Mr. Zhang Fengliang , with an average transaction price of 16.61 yuan/share and a transaction amount of 36,542 yuan. On July 18, 2017, 500 shares of the company's stock were sold, with an average transaction price of 17.392 yuan/share, the transaction amount was 8,696 yuan, with a gain of 391.00 yuan. Up to now, Mr. Zhang Fengliang holds 1,700 shares. As the company disclosed the 2017 semi-annual performance forecast on July 18, 2017, the above-mentioned transactions violated the "Rules for the Management of the Company's Shares Held by Directors, Supervisors and Senior Managers of Listed Companies and Their Changes" and "Shareholders of Listed Companies, Directors, Supervisors, and Senior Management Several Provisions on Shareholding Reduction" violated the provisions of Article 47 of the "Securities Law" and constituted short-term trading and sensitive period trading.
Handling of 2. mattersAs a senior manager of the company, Mr. Zhang Fengliang neglected to effectively convey and transmit relevant laws and regulations and securities trading rules to his family, resulting in illegal trading of company stocks in his securities account. The board of directors of the company made the following decision on Mr. Zhang Fengliang's illegal behavior:
1
, the company has made serious criticism and education to Mr. Zhang Fengliang, it is required to seriously study the securities law, the Listing Rules of Shanghai Stock Exchange, the rules on the management of shares held by directors, supervisors and senior managers of listed companies and their changes, and provisions on the reduction of shares held by shareholders, directors, supervisors and senior managers of listed companies and other relevant laws, regulations and normative documents, and require them to be strictly implemented.
2, Mr. Zhang Fengliang's illegal transaction resulted in income 391.00 yuan. The board of directors of the company collected the illegal income from him in accordance with relevant regulations and imposed a fine of three times (1173 yuan) from the transaction as a minor punishment.
3, Mr. Zhang Fengliang himself made a deep reflection on this illegal trading of the company's shares, and promised to withdraw his account and restrain his family's stock trading behavior to avoid the recurrence of such incidents.
4, the board of directors requires the remaining 1700 shares of the company not to reduce their holdings during the company's tenure.
5. The board of directors of the company notified all directors, supervisors and senior managers of the company of this matter, and criticized Mr. Zhang Fengliang within the company, requiring all directors, supervisors and senior managers of the company to take this as a warning, strengthen the study of relevant laws and regulations, strengthen the management of securities accounts, and strictly regulate the behavior of buying and selling company stocks.
3. Other Supplementary DisclosuresMr. Zhang Fengliang deeply regrets the occurrence of this illegal transaction, is willing to accept the above handling decision made by the board of directors of the company, and sincerely apologizes to the investors for this illegal transaction.
The company will further strengthen the organization of directors, supervisors, and senior management to the "Securities Law", "Shanghai Stock Exchange Stock Listing Rules",
"The Company's Shares Held by Directors, Supervisors and Senior Management of Listed Companies" and "Regulations on the Reduction of Shares by Shareholders, Directors, Supervisors and Senior Executers' Shares" and other relevant laws, regulations, and regulatory documents study, it also requires all relevant personnel themselves and their relatives to strictly abide by the relevant regulations to prevent the recurrence of such situations.
hereby announcesZhejiang Jianfeng Group Co., Ltd. Board of Directors
July 20, 2017
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page